Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease
Authors: Esther Meijer, Folkert W. Visser, Rene M. M. van Aerts, Charles J. Blijdorp, Niek F. Casteleijn, Hedwig M. A. D‘Agnolo, Shosha E. I. Dekker, Joost P. H. Drenth, Johan W. de Fijter, Maatje D. A. van Gastel, Tom J. Gevers, Marten A. Lantinga, Monique Losekoot, A. Lianne Messchendorp, Myrte K. Neijenhuis, Michelle J. Pena, Dorien J. M. Peters, Mahdi Salih, Darius Soonawala, Edwin M. Spithoven, Jack F. Wetzels, Robert Zietse, Ron T. Gansevoort
Journal: JAMA (2018)

<h3>Importance</h3> Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation in both kidneys and loss of renal function, eventually leading to a need for kidney replacement therapy. There are limited therapeutic management options. <h3>Objective</h3> To examine the effect of the somatostatin analogue lanreotide on the rate of kidney function loss in patients with later-stage ADPKD. <h3>Design, Setting, and Participants</h3> An open-label randomized clinical trial with blinded end point assessment that included 309 patients with ADPKD from July 2012 to March 2015 at 4 nephrology outpatient clinics in the Netherlands. Eligible patients were 18 to 60 years of age and had an estimated glomerular filtration rate (eGFR) of 30 to 60 mL/min/1.73 m<sup>2</sup>. Follow-up of the 2.5-year trial ended in August 2017. <h3>Interventions</h3> Patients were randomized to receive either lanreotide (120 mg subcutaneously once every 4 weeks) in addition to standard care (n = 153) or standard care only (target blood pressure &lt;140/90 mm Hg; n = 152). <h3>Main Outcomes and Measures</h3> Primary outcome was annual change in eGFR assessed as slope through eGFR values during the 2.5-year treatment phase. Secondary outcomes included change in eGFR before vs after treatment, incidence of worsening kidney function (start of dialysis or 30% decrease in eGFR), change in total kidney volume and change in quality of life (range: 1 [not bothered] to 5 [extremely bothered]). <h3>Results</h3> Among the 309 patients who were randomized (mean [SD] age, 48.4 [7.3] years; 53.4% women), 261 (85.6%) completed the trial. Annual rate of eGFR decline for the lanreotide vs the control group was −3.53 vs −3.46 mL/min/1.73 m<sup>2</sup>per year (difference, −0.08 [95% CI, −0.71 to 0.56];<i>P</i> = .81). There were no significant differences for incidence of worsening kidney function (hazard ratio, 0.87 [95% CI, 0.49 to 1.52];<i>P</i> = .87), change in eGFR (−3.58 vs −3.45; difference, −0.13 mL/min/1.73 m<sup>2</sup>per year [95% CI, −1.76 to 1.50];<i>P</i> = .88), and change in quality of life (0.05 vs 0.07; difference, −0.03 units per year [95% CI, −0.13 to 0.08];<i>P</i> = .67). The rate of growth in total kidney volume was lower in the lanreotide group than the control group (4.15% vs 5.56%; difference, −1.33% per year [95% CI, −2.41% to −0.24%];<i>P</i> = .02). Adverse events in the lanreotide vs control group included injection site discomfort (32% vs 0.7%), injection site papule (5.9% vs 0%), loose stools (91% vs 6.6%), abdominal discomfort (79% vs 20%), and hepatic cyst infections (5.2% vs 0%). <h3>Conclusions and Relevance</h3> Among patients with later-stage autosomal dominant polycystic kidney disease, treatment with lanreotide compared with standard care did not slow the decline in kidney function over 2.5 years of follow-up. These findings do not support the use of lanreotide for treatment of later-stage autosomal dominant polycystic kidney disease. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT01616927